Dihydrocodeine Tartrate

證據等級: L5

預測適應症: 0 個

DIHYDROCODEINE TARTRATE: Repurposing Analysis — Insufficient Evidence for Evaluation

One-Sentence Summary

Dihydrocodeine Tartrate is an opioid-class analgesic and antitussive agent whose regulatory and pharmacological data could not be fully retrieved in this analysis cycle. The TxGNN model returned no predicted new indications for this compound, and the drug is not marketed in New Zealand, leaving critical data gaps that prevent a complete repurposing evaluation. Without predicted indications, clinical trial linkage, or confirmed mechanism-of-action data, this candidate cannot proceed past the intake stage.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and none present)
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this Evidence Pack. Based on general pharmacological knowledge, Dihydrocodeine Tartrate is a semi-synthetic opioid derived from codeine. It binds to µ-opioid receptors in the central nervous system to produce analgesic and antitussive effects, and is typically indicated for moderate-to-severe pain and non-productive cough.

However, because original_moa is flagged as a data gap (DG002) and original_indications was not populated in this submission, this evaluation cannot formally verify the mechanistic basis for any proposed repurposing direction.

The TxGNN model produced zero predicted indications, which may reflect insufficient graph coverage for this compound or that the drug was not represented in the training knowledge graph under this name/salt form. This is a critical issue requiring upstream investigation before proceeding.

Clinical Trial Evidence

Currently no related clinical trials registered under this Evidence Pack's predicted indications (no indications returned by TxGNN).

Literature Evidence

Currently no related literature available within this Evidence Pack (no indications returned by TxGNN to anchor a literature search).

New Zealand Market Information

This drug is not marketed in New Zealand. No authorizations on record.

Safety Considerations

Please refer to the package insert for safety information.

Note: Both key_warnings and contraindications were returned as data gaps (DG001). The DDI query returned no interactions. As Dihydrocodeine Tartrate is an opioid, standard opioid-class warnings (respiratory depression, dependence liability, CNS depression interactions) should be assumed until formal package insert data is retrieved.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model returned no predicted indications for this compound, and two blocking/high-severity data gaps (package insert warnings and mechanism of action) remain unresolved. There is no evidence base on which to conduct a repurposing evaluation at this time.

To proceed, the following is needed:

DG001 (Blocking): Retrieve TFDA package insert PDF and extract warnings and contraindications — this is a prerequisite for safety screening
DG002 (High): Query DrugBank API to confirm mechanism of action and pharmacological class
TxGNN re-run: Verify whether the compound is indexed in the TxGNN knowledge graph under its INN or an alternative identifier (e.g., "dihydrocodeine" without the salt suffix); re-run prediction pipeline if necessary
Regulatory baseline: Confirm whether any international regulatory bodies (EMA, FDA, PMDA) hold approvals that can serve as a proxy indication profile
DrugBank ID resolution: The drugbank_id field is null — this must be resolved to enable DDI lookups and pharmacological class assignment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.